Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) will release its first quarter 2026 financial results on Thursday, May 14, 2026 after market close. A live conference call and webcast will follow at 4:30 p.m. ET with CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson.

The webcast will be available at ir.co-dx.com on the Events & Webcasts page; a recorded replay will be posted later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – CODX

+1.31%

1 alert

+1.31% News Effect

+$77K Valuation Impact

$5.94M Market Cap

0.2x Rel. Volume

On the day this news was published, CODX gained 1.31%, reflecting a mild positive market reaction. This price movement added approximately $77K to the company's valuation, bringing the market cap to $5.94M at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement sets expectations for Co-Diagnostics’ Q1 2026 earnings release on May 14, 2026 and...

Analysis

This announcement sets expectations for Co-Diagnostics’ Q1 2026 earnings release on May 14, 2026 and details an investor webcast at 4:30 p.m. ET. In the months prior, filings highlighted sharp 2025 losses, reduced cash, and going-concern warnings, alongside ongoing regulatory efforts for its PCR platform. Investors may focus on upcoming revenue trends, cash levels, and regulatory milestones when the full results are reported.

Key Figures

Earnings release date: May 14, 2026 Earnings call time: 4:30 p.m. ET Conference call (toll-free): 1-888-880-3330 +1 more

4 metrics

Earnings release date May 14, 2026 Q1 2026 financial results to be released after market close

Earnings call time 4:30 p.m. ET Q1 2026 conference call and webcast start time

Conference call (toll-free) 1-888-880-3330 Dial-in number for U.S. participants

Conference call (toll) 1-646-357-8766 Dial-in number for international participants

Previous Earnings date Reports

2 past events · Latest: Mar 17 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 17	Earnings date notice	Neutral	-8.4%	Announcement of Q4 and full year 2025 earnings release date and webcast.
Apr 30	Earnings date notice	Neutral	+0.0%	Announcement of Q1 2026 earnings release date and investor webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior earnings date announcement coincided with a negative -8.4% move, suggesting the market has previously reacted cautiously to simple scheduling updates.

Recent Company History

In recent months, CODX has reported sharply weaker 2025 results, with revenue down and significant operating losses, alongside going-concern warnings in its 10-K. Operational updates highlighted regulatory progress and joint ventures in India and Saudi Arabia, plus conference participation to showcase its PCR platform, which remains under regulatory review. Against this backdrop, the current Q1 2026 earnings date notice continues a pattern of routine investor communications following substantive financial disclosures.

Historical Comparison

-8.4% avg move · Past earnings-date news for CODX saw an average -8.4% move, indicating that even routine scheduling ...

earnings date

-8.4%

Average Historical Move earnings date

Past earnings-date news for CODX saw an average -8.4% move, indicating that even routine scheduling updates have previously coincided with notable downside volatility.

The company has issued repeated earnings date notices with similar webcast formats, following major financial result announcements and maintaining consistent communication practices.

Regulatory & Risk Context

Short Interest: 29.37%

Short Interest

29.37% of float

0% 15% 30%+

high as of 2026-05-29 Days to cover: 1

Key Terms

molecular diagnostics

1 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here

Conference Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-announces-first-quarter-2026-earnings-release-date-and-webcast-302758752.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) release Q1 2026 earnings and what time is the webcast?

Co-Diagnostics will release Q1 2026 results on May 14, 2026 after market close, with a webcast at 4:30 p.m. ET. According to the company, the conference call and webcast will discuss the quarter and feature senior management commentary and Q&A with analysts.

How can investors join the CODX May 14, 2026 earnings conference call and webcast?

Investors can join the webcast at ir.co-dx.com or call 1-888-880-3330 (toll free) or 1-646-357-8766 (toll). According to the company, the live event will be accessible on the Events & Webcasts page and later available as a recorded replay.

Who will speak for Co-Diagnostics on the Q1 2026 earnings call (CODX)?

Speakers include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. According to the company, these executives will present financial results, discuss operational highlights, and answer analyst questions during the webcast and call.

Will Co-Diagnostics (CODX) provide a replay if I miss the live May 14, 2026 webcast?

Yes. According to the company, the conference call will be recorded and later made available on the company's website. The replay will be posted on the Events & Webcasts page at ir.co-dx.com after the live broadcast for on-demand access.

What topics will Co-Diagnostics cover during the May 14, 2026 CODX earnings call?

The company will discuss Q1 2026 financial results and related analyst questions during the webcast and call. According to Co-Diagnostics, management will offer commentary on performance and respond to analyst inquiries but no additional event-specific materials were announced in the release.